These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
735 related articles for article (PubMed ID: 23452071)
1. Is there a difference between women with or without detrusor overactivity complaining of symptoms of overactive bladder? Giarenis I; Mastoroudes H; Srikrishna S; Robinson D; Cardozo L BJU Int; 2013 Aug; 112(4):501-7. PubMed ID: 23452071 [TBL] [Abstract][Full Text] [Related]
3. Clinical and urodynamic impact of detrusor overactivity in women with overactive bladder. Jiménez-Cidre MA; López-Fando L; Mora AM; Actas Urol Esp (Engl Ed); 2019 Jun; 43(5):221-227. PubMed ID: 30862379 [TBL] [Abstract][Full Text] [Related]
4. Association of symptoms with urodynamic findings in men with overactive bladder syndrome. Al-Zahrani AA; Gajewski JB BJU Int; 2012 Dec; 110(11 Pt C):E891-5. PubMed ID: 22928556 [TBL] [Abstract][Full Text] [Related]
5. Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome. Chung SD; Liao CH; Chen YC; Kuo HC Neurourol Urodyn; 2011 Sep; 30(7):1300-4. PubMed ID: 21560153 [TBL] [Abstract][Full Text] [Related]
6. The impact of tension-free vaginal tape on overactive bladder symptoms in women with stress urinary incontinence: significance of detrusor overactivity. Choe JH; Choo MS; Lee KS J Urol; 2008 Jan; 179(1):214-9. PubMed ID: 18001792 [TBL] [Abstract][Full Text] [Related]
7. A prospective assessment of overactive bladder symptoms in a cohort of elderly women who underwent transvaginal surgery for advanced pelvic organ prolapse. Foster RT; Barber MD; Parasio MF; Walters MD; Weidner AC; Amundsen CL Am J Obstet Gynecol; 2007 Jul; 197(1):82.e1-4. PubMed ID: 17618768 [TBL] [Abstract][Full Text] [Related]
8. Use of near infrared spectroscopy as an alternative to videourodynamics to detect detrusor overactivity in women with the overactive bladder syndrome. Mastoroudes H; Giarenis I; Vella M; Srikrishna S; Robinson D; Cardozo L; Karrouze I; Campbell A; Macnab A Urology; 2012 Sep; 80(3):547-50. PubMed ID: 22840868 [TBL] [Abstract][Full Text] [Related]
9. Understanding the elements of overactive bladder: questions raised by the EPIC study. Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K; BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602 [TBL] [Abstract][Full Text] [Related]
10. Is there any association between urodynamic variables and severity of overactive bladder in women with idiopathic detrusor overactivity? Giarenis I; Zacchè M; Robinson D; Cardozo L Neurourol Urodyn; 2017 Mar; 36(3):780-783. PubMed ID: 27092808 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder. Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844 [TBL] [Abstract][Full Text] [Related]
12. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China. Wang Y; Xu K; Hu H; Zhang X; Wang X; Na Y; Kang X Neurourol Urodyn; 2011 Nov; 30(8):1448-55. PubMed ID: 21826714 [TBL] [Abstract][Full Text] [Related]
13. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). Cardozo L; Amarenco G; Pushkar D; Mikulas J; Drogendijk T; Wright M; Compion G; BJU Int; 2013 May; 111(5):804-10. PubMed ID: 23294801 [TBL] [Abstract][Full Text] [Related]
14. [The influence of mesh pelvic floor reconstructive surgery on OAB symptoms]. Nowakowski L; Wróbel A; Jankiewicz K; Kulik-Rechberger B; Rechberger T Ginekol Pol; 2014 Oct; 85(10):760-4. PubMed ID: 25546927 [TBL] [Abstract][Full Text] [Related]
15. Comparison of fesoterodine and tolterodine in patients with overactive bladder. Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298 [TBL] [Abstract][Full Text] [Related]
16. Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle. Dokmeci F; Cetinkaya SE; Seval MM; Dai O Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():126-131. PubMed ID: 28355584 [TBL] [Abstract][Full Text] [Related]
17. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995 [TBL] [Abstract][Full Text] [Related]
18. Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder. Khullar V; Cardozo L; Kelleher CJ; Hall T; Ryan J; Ebel Bitoun C; Darekar A; Arumi D; Wagg A BJU Int; 2013 Oct; 112(6):820-9. PubMed ID: 23465055 [TBL] [Abstract][Full Text] [Related]
19. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014 [TBL] [Abstract][Full Text] [Related]
20. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug. Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]